What do Spanish registries report about worsening events in chronic heart failure? Needs and challenges.

IF 1.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 DOI:10.1080/14779072.2023.2215985
Juan Luis Bonilla Palomas, José Ignacio Morgado García de Polavieja, Miriam Padilla Pérez, Diego Rangel-Sousa, Antonio Castro Fernández, José López Aguilera, Carolina Ortiz Cortés, Francisco Torres Calvo
{"title":"What do Spanish registries report about worsening events in chronic heart failure? Needs and challenges.","authors":"Juan Luis Bonilla Palomas,&nbsp;José Ignacio Morgado García de Polavieja,&nbsp;Miriam Padilla Pérez,&nbsp;Diego Rangel-Sousa,&nbsp;Antonio Castro Fernández,&nbsp;José López Aguilera,&nbsp;Carolina Ortiz Cortés,&nbsp;Francisco Torres Calvo","doi":"10.1080/14779072.2023.2215985","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Worsening heart failure (HF) is associated with a high risk of death and rehospitalization. Despite that, real world evidence about the impact of worsening HF on clinical practice is scarce.</p><p><strong>Areas covered: </strong>A narrative review about registries addressing recent worsening HF events in Spain, with special emphasis on patients recently hospitalized for HF was performed.</p><p><strong>Expert opinion: </strong>Worsening HF can be defined as situations where the patient's HF deteriorates to the extent that it necessitates initiation or intensification of diuretic treatment (mainly intravenous). The events can occur at the outpatient level, generally in the day hospital, in the emergency department or even hospitalization. Early identification of worsening HF events is essential to establish appropriate treatment as soon as possible. In this context, robust clinical benefits have been reported for renin-angiotensin system inhibitors, sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and vericiguat. In Spain, several registries of patients with HF have been developed, some of them including patients recently hospitalized for HF, but not with recent worsening HF events. Therefore, registries addressing recent worsening events would be desirable. Using a practical approach, this review analyzes the importance of worsening HF events, with special emphasis on Spanish data.</p>","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Cardiovascular Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14779072.2023.2215985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Worsening heart failure (HF) is associated with a high risk of death and rehospitalization. Despite that, real world evidence about the impact of worsening HF on clinical practice is scarce.

Areas covered: A narrative review about registries addressing recent worsening HF events in Spain, with special emphasis on patients recently hospitalized for HF was performed.

Expert opinion: Worsening HF can be defined as situations where the patient's HF deteriorates to the extent that it necessitates initiation or intensification of diuretic treatment (mainly intravenous). The events can occur at the outpatient level, generally in the day hospital, in the emergency department or even hospitalization. Early identification of worsening HF events is essential to establish appropriate treatment as soon as possible. In this context, robust clinical benefits have been reported for renin-angiotensin system inhibitors, sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and vericiguat. In Spain, several registries of patients with HF have been developed, some of them including patients recently hospitalized for HF, but not with recent worsening HF events. Therefore, registries addressing recent worsening events would be desirable. Using a practical approach, this review analyzes the importance of worsening HF events, with special emphasis on Spanish data.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于慢性心力衰竭的恶化事件,西班牙登记处报告了什么?需求和挑战。
心衰(HF)恶化与死亡和再住院的高风险相关。尽管如此,关于心衰恶化对临床实践影响的真实证据很少。涵盖领域:对西班牙近期心衰恶化事件的登记进行了叙述性回顾,特别强调了最近因心衰住院的患者。专家意见:心衰恶化可以定义为患者心衰恶化到需要开始或加强利尿剂治疗(主要是静脉注射)的情况。这些事件可以发生在门诊阶段,一般在日间医院、急诊科甚至住院。早期识别恶化的心衰事件对于尽快确定适当的治疗至关重要。在此背景下,肾素-血管紧张素系统抑制剂、苏比特利-缬沙坦、β受体阻滞剂、矿皮质激素受体拮抗剂、SGLT2抑制剂和vericiguat的临床疗效已经得到了强有力的报道。在西班牙,已经建立了几个心衰患者的登记处,其中一些包括最近因心衰住院的患者,但不包括最近心衰事件恶化的患者。因此,处理最近恶化事件的注册表是可取的。本文采用实用的方法分析了心衰事件恶化的重要性,特别强调了西班牙的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Cardiovascular Therapy
Expert Review of Cardiovascular Therapy CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
0.00%
发文量
82
期刊介绍: Expert Review of Cardiovascular Therapy (ISSN 1477-9072) provides expert reviews on the clinical applications of new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage includes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of research or clinical practice.
期刊最新文献
Beyond pulmonary vein isolation: approaches to treat patients with persistent atrial fibrillation. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now? Cerebral embolic protection for stroke prevention during transcatheter aortic valve replacement. PTSD and mood disorders in implantable cardioverter defibrillator patients: is more psychological assessment needed? Long-term outcomes following bioresorbable vascular scaffolds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1